TY - JOUR T1 - Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review JO - Reumatología Clínica T2 - AU - Álvarez-Rivas,Noelia AU - Sang-Park,Hye AU - Díaz del Campo,Petra AU - Fernández-Castro,Mónica AU - Corominas,Hector AU - Andreu,José Luis AU - Navarro-Compán,Victoria SN - 1699258X M3 - 10.1016/j.reuma.2020.03.003 DO - 10.1016/j.reuma.2020.03.003 UR - https://www.reumatologiaclinica.org/es-efficacy-belimumab-in-primary-sjogren39s-articulo-S1699258X20300760 AB - ObjectiveTo evaluate the efficacy and safety of belimumab in patients with Primary Sjögren's syndrome (pSS). MethodsThe search included manuscripts assessing the efficacy or safety of belimumab in patients with pSS (American-European Consensus Criteria 2002) published between 2004 and 2017 in MEDLINE, EMBASE or Cochrane databases. Two reviewers independently selected the articles, extracted data and evaluated the quality of the evidence following Scottish Intercollegiate Guidelines Network (SIGN) recommendation grades. ResultsOut of 135 citations, only 3 articles were included. All of them publishing results from the same study at different time points including 28 patients. At week 28 improvement was reported for visual analogue scale (VAS) dryness score and glandular manifestations in 37% and 77% of patients, respectively, which persisted at week 52 (W52). Belimumab was well tolerated and safely administered. ConclusionPublished evidence to determine the efficacy of belimumab in pSS is limited. Belimumab seems to be effective to reduce systemic activity, parotid enlargement, lymphadenopathies, articular manifestation and B cell biomarkers. ER -